Paired exome analysis of Barrett's esophagus and adenocarcinoma

Nature Genetics

Volumn 47, Issue 9, 2015, Pages 1047-1055

  Stachler, Matthew D ^a,b   Taylor Weiner, Amaro ^c   Peng, Shouyong ^b   McKenna, Aaron ^d   Agoston, Agoston T ^a   Odze, Robert D ^a   Davison, Jon M ^e   Nason, Katie S ^e   Loda, Massimo ^a,b   Leshchiner, Ignaty ^c   Stewart, Chip ^c   Stojanov, Petar ^c   Seepo, Sara ^c   Lawrence, Michael S ^c   Ferrer Torres, Daysha ^f   Lin, Jules ^f   Chang, Andrew C ^f   Gabriel, Stacey B ^c   Lander, Eric S ^c,g   Beer, David G ^f   Getz, Gad ^c,h   Carter, Scott L ^b,c,i   Bass, Adam J ^b,c   more..

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^f UNIVERSITY OF MICHIGAN   (United States)

^g MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

ⁱ HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; PROTEIN P53; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN; TP53 PROTEIN, HUMAN;

ARTICLE; BARRETT ESOPHAGUS; CANCER GROWTH; CLINICAL ARTICLE; ESOPHAGEAL ADENOCARCINOMA; EXOME; GENE AMPLIFICATION; GENE MUTATION; GENE SEQUENCE; GENOME; GENOMICS; HUMAN; LASER CAPTURE MICRODISSECTION; ONCOGENE; PRIORITY JOURNAL; ADENOCARCINOMA; DNA MUTATIONAL ANALYSIS; ESOPHAGUS TUMOR; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETICS; GENOME-WIDE ASSOCIATION STUDY; POINT MUTATION;

ADENOCARCINOMA; BARRETT ESOPHAGUS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA MUTATIONAL ANALYSIS; ESOPHAGEAL NEOPLASMS; EXOME; GENE AMPLIFICATION; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; PHOSPHATIDYLINOSITOL 3-KINASES; POINT MUTATION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84940587003     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng.3343     Document Type: Article

References (63)

1. Nehra, D., Howell, P. , Williams, C.P., Pye, J.K. & Beynon, J. Toxic bile acids in gastro-oesophageal refux disease: infuence of gastric acidity. Gut 44, 598-602 (1999).
2. Wild, C.P. & Hardie, L.J. Refux, Barrett's oesophagus and adenocarcinoma: burning questions. Nat. Rev. Cancer 3, 676-684 (2003).
3. Lagergren, J., Bergstromeinhold, R., Lingren, A. & Nyren, O. Symptomatic gastoroesophageal refux as a risk factor for esophageal adenocarcinoma. N. Engl. J. Med. 340, 825-831 (1999).
4. Ormsby, A.H. et al. The location and frequency of intestinal metaplasia at the esophagogastric junction in 223 consecutive autopsies: implications for patient treatment and preventive strategies in Barrett's esophagus. Mod. Pathol. 13, 614-620 (2000).
5. Galipeau, P.C., Prevo, L.J., Sanchez, C.a., Longton, G.M. & Reid, B.J. Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue. J. Natl. Cancer Inst. 91, 2087-2095 (1999).
6. Gu, J. et al. Genome-wide catalogue of chromosomal aberrations in Barrett's esophagus and esophageal adenocarcinoma: a high-density single nucleotide polymorphism array analysis. Cancer Prev. Res. (Phila.) 3, 1176-1186 (2010).
7. Li, X. et al. Temporal and spatial evolution of somatic chromosomal alterations: a case-cohort study of Barrett's esophagus. Cancer Prev. Res. (Phila.) 7, 114-127 (2014).
8. Li, X. et al. Single nucleotide polymorphism-based genome-wide chromosome copy change, loss of heterozygosity, and aneuploidy in Barrett's esophagus neoplastic progression. Cancer Prev. Res. (Phila.) 1, 413-423 (2008).
9. Reid, B.J. et al. Barrett's esophagus: ordering the events that lead to cancer. Eur. J. Cancer Prev. 5, 57-65 (1996).
10. INK4a lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium. Cancer Res. 61, 8284-8289 (2001).
11. Zhang, S. & Wang, X.I. SIRT1 is a useful biomarker for high-grade dysplasia and carcinoma in Barrett's. Esophagus 43, 373-377 (2013).
12. Paulson, T.G. et al. p16 mutation spectrum in the premalignant condition Barrett's esophagus. PLoS ONE 3, e3809 (2008).
13. Dulak, A.M. et al. Exome and whole genome sequencing of esophageal adenocarcinoma identifes recurrent driver events and mutational complexity. Nat. Genet. 45, 478-486 (2013).
14. Carter, S.L. et al. Absolute quantifcation of somatic DNA alterations in human cancer. Nat. Biotechnol. 30, 413-421 (2012).
15. Dulak, A.M. et al. Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis. Cancer Res. 72, 4383-4393 (2012).
16. Fujiwara, T. et al. Cytokinesis failure generating tetraploids promotes tumorigenesis in p53-null cells. Nature 437, 1043-1047 (2005).
17. Davoli, T. & de Lange, T. Telomere-driven tetraploidization occurs in human cells undergoing crisis and promotes transformation of mouse cells. Cancer Cell 21, 765-776 (2012).
18. Zack, T.I. et al. Pan-cancer patterns of somatic copy number alteration. Nat. Genet. 45, 1134-1140 (2013).
19. Etemadmoghadam, D. et al. Resistance to CDK2 inhibitors is associated with selection of polyploid cells in CCNE1-amplifed ovarian cancer. Clin. Cancer Res. 19, 5960-5971 (2013).
20. Maley, C.C. et al. Selectively advantageous mutations and hitchhikers in neoplasms: p16 lesions are selected in Barrett's esophagus. Cancer Res. 64, 3414-3427 (2004).
21. Weaver, J.M.J. et al. Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis. Nat. Genet. 46, 837-843 (2014).
22. Maley, C.C. et al. Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat. Genet. 38, 468-473 (2006).
23. Reid, B.J. et al. Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifes a patient subset at increased risk for neoplastic progression. Am. J. Gastroenterol. 96, 2839-2848 (2001).
24. van Wyk, R. et al. Somatic mutations of the APC, KRAS, and TP53 genes in nonpolypoid colorectal adenomas. Genes Chromosom. Cancer 27, 202-208 (2000).
25. Prestlow, T.P. & Prestlow, T.G. No mutant KRAS in aberrant crypt foci (ACF): initiation of colorectal cancer? Biochim. Biophys. Acta 1756, 83-96 (2005).
26. Lüttges, J. et al. The K-ras mutation pattern in pancreatic ductal adenocarcinoma usually is identical to that in associated normal, hyperplastic, and metaplastic ductal epithelium. Cancer 85, 1703-1710 (1999).
27. Deramaudt, T. & Rustgi, A. Mutant KRAS in the initiation of pancreatic cancer. Biochim. Biophys. Acta 1756, 97-101 (2005).
28. Gordon, D.J., Resio, B. & Pellman, D. Causes and consequences of aneuploidy in cancer. Nat. Rev. Genet. 13, 189-203 (2012).
29. Dewhurst, S.M. et al. Tolerance of whole-genome doubling propagates chromosomal instability and accelerates cancer genome evolution. Cancer Discov. 4, 175-185 (2014).
30. Davoli, T. & de Lange, T. The causes and consequences of polyploidy in normal development and cancer. Annu. Rev. Cell Dev. Biol. 27, 585-610 (2011).
31. Ganem, N.J. et al. Cytokinesis failure triggers Hippo tumor suppressor pathway activation. Cell 158, 833-848 (2014).
32. Nones, K. et al. Genomic catastrophes frequently arise in esophageal adenocarcinoma and drive tumorigenesis. Nat. Commun. 5, 5224 (2014).
33. Rabinovitch, P.S., Reid, B.J., Haggit, R.C., Norwood, T.H. & Rubin, C.E. Progression to cancer in Barrett's esophagus is associated with genomic instability. Lab. Invest. 60, 65-71 (1989).
34. Davelaar, A.L. et al. Aberrant TP53 detected by combining immunohistochemistry and DNA-FISH improves Barrett's esophagus progression prediction: a prospective follow-up study. Genes Chromosom. Cancer 54, 82-90 (2015).
35. Bytzer, P. , Christensen, P.B., Damkier, P., Vinding, K. & Seersholm, N. Adenocarcinoma of the esophagus and Barrett's esophagus: a population-based study. Am. J. Gastroenterol. 94, 86-91 (1999).
36. Weston, A.P. et al. Long-term follow-up of Barrett's high-grade dysplasia. Am. J. Gastroenterol. 95, 1888-1893 (2000).
37. Corley, D.A., Levin, T.R., Habel, L.A., Weiss, N.S. & Buffer, P.A. Surveillance and survival in Barrett's adenocarcinomas: a population-based study. Gastroenterology 122, 633-640 (2002).
38. Hvid-Jensen, F. , Pedersen, L., Drewes, A., Sorensen, H. & Funch-Jensen, P. Incidence of adenocarcinoma among patients with Barrett's esophagus. N. Engl. J. Med. 365, 1375-1383 (2011).
39. Fisher, S. et al. A scalable, fully automated process for construction of sequence-ready human exome targeted capture libraries. Genome Biol. 12, R1 (2011).
40. Berger, M.F. et al. The genomic complexity of primary human prostate cancer. Nature 470, 214-220 (2011).
41. Chapman, M.A. et al. Initial genome sequencing and analysis of multiple myeloma. Nature 471, 467-472 (2011).
42. Barbieri, C.E. et al. Exome sequencing identifes recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat. Genet. 44, 685-689 (2012).
43. Stransky, N. et al. The mutational landscape of head and neck squamous cell carcinoma. Science 333, 1157-1160 (2011).
44. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609-615 (2011).
45. Cibulskis, K. et al. ContEst: estimating cross-contamination of human samples in next-generation sequencing data. Bioinformatics 27, 2601-2602 (2011).
46. Fujita, P.A. et al. The UCSC Genome Browser database: update 2011. Nucleic Acids Res. 39, D876-D882 (2011).
47. Sherry, S.T. et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 29, 308-311 (2001).
48. Griffth, O.L. et al. ORegAnno: an open-access community-driven resource for regulatory annotation. Nucleic Acids Res. 36, D107-D113 (2008).
49. UniProt Consortium. Ongoing and future developments at the Universal Protein Resource. Nucleic Acids Res. 39, D214-D219 (2011).
50. Forbes, S.A. et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 39, D945-D950 (2011).
51. Venkatraman, E.S. & Olshen, A.B. A faster circular binary segmentation algorithm for the analysis of array CGH data. Bioinformatics 23, 657-663 (2007).
52. Olshen, A.B. et al. Parent-specifc copy number in paired tumor-normal studies using circular binary segmentation. Bioinformatics 27, 2038-2046 (2011).
53. Landau, D.A. et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 152, 714-726 (2013).
54. Lohr, J.G., Stojanov, P. , Carter, S.L., Cruz-gordillo, P. & Lawrence, M.S. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell 25, 91-101 (2014).
55. Campbell, P.J. et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 467, 1109-1113 (2010).
56. Gerlinger, M. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883-892 (2012).
57. Liu, W. et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat. Med. 15, 559-565 (2009).
58. Navin, N. et al. Tumour evolution inferred by single-cell sequencing. Nature 472, 90-94 (2011).
59. Shah, S.P. et al. Mutational evolution in a lobular breast tumour profled at single nucleotide resolution. Nature 461, 809-813 (2009).
60. Nik-Zainal, S. et al. Mutational processes molding the genomes of 21 breast cancers. Cell 149, 979-993 (2012).
61. McFadden, D.G. et al. Genetic and clonal dissection of murine small cell lung carcinoma progression by genome sequencing. Cell 156, 1298-1311 (2014).
62. Nixon, K.C. The Parsimony Ratchet, a new method for rapid parsimony analysis. Cladistics 15, 407-414 (1999).
63. Lawrence, M.S. et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499, 214-218 (2013).